Latest News
Research
VCU Massey researchers receive $18.1 million grant to lead a public health study on tobacco
Sep 25, 2013

Eissenberg and Balster researchers have received an $18.1 million federal grant – VCU’s third largest to date – to study so-called modified risk tobacco products and other novel tobacco products, such as electronic cigarettes, and to develop an evaluation tool to help inform United States tobacco regulatory policy.
Co-principal investigators Thomas Eissenberg, Ph.D., and Robert Balster, Ph.D., both members of the Cancer Prevention and Control research program at Massey and faculty of the VCU Department of Psychology’s Center for the Study of Tobacco Products in the College of Humanities and Sciences, will lead a VCU-wide initiative to study methods for evaluating modified risk tobacco products, or MRTPs. VCU is one of 14 institutions that provide vital scientific evidence to the Tobacco Centers of Regulatory Science, a new program launched by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health.
The group will develop and test a multidisciplinary approach that uses engineering, clinical behavioral research and randomized control trials to study the effects of novel tobacco products. The information learned from this research will help implement the 2009 Family Smoking Prevention and Tobacco Control Act, which gave the FDA the authority to regulate the manufacturing, distribution and marketing of tobacco products to protect public health.
“This historic grant signifies that Virginia Commonwealth University is a national leader in our unique commitment to human health,” said Michael Rao, Ph.D., president of VCU and VCU Health System. “It is the result of the multidisciplinary collaborative spirit that is ubiquitous at VCU and the VCU Health System, and it serves to remind us that our focus is really on people.”
“For the first time, under the Family Smoking Prevention and Tobacco Control Act, the federal government, through the FDA Center for Tobacco Products, is able to bring science-based regulation to the manufacturing, marketing and distribution of tobacco products,” said FDA Commissioner Margaret A. Hamburg, M.D. “The FDA is committed to a science-based approach that addresses the complex public health issues raised by tobacco product regulation.”
The multi-year grant will involve four components — examination of factors that influence MRTP nicotine and toxicant yield; comparison of short-term effects of MRTP to other products; a randomized control trial; and MRTP use and misuse on user’s attitudes, beliefs and perceived effects.
“While the focus of the Center for the Study of Tobacco Products is on novel tobacco products generally, this grant will also allow us to provide a wealth of information regarding electronic cigarettes and is designed to have the flexibility and capacity to begin new research to address issues raised in today’s rapidly evolving tobacco marketplace,” Eissenberg said.
“I am especially pleased that one of the missions of the new center is to develop training programs for a new generation of tobacco regulatory scientists,” Balster said. “Support is provided for both graduate students in behavioral and biomedical sciences as well as for post-doctoral research fellows.”
VCU’s center is part of a network of Tobacco Centers of Regulatory Science that includes Yale, Ohio State, the University of North Carolina and the University of Southern California, Los Angeles. The program will be coordinated by the National Institutes of Health Tobacco Regulatory Science Program. The VCU grant that forms the Center for the Study of Tobacco Products includes two partner institutions: Penn State-Hershey, with Jonathan Foulds, Ph.D., and the American University of Beirut, with Alan Shihadeh, Sc.D.
Re-purposed from an article by Cheryle Rodriguez, University Public Affairs
Written by: Alaina Schneider
Related News
Research
“We’re aiming for a cure.” Massey and VIMM researchers achieve potential breakthrough in brain cancer treatmentJun 24, 2025
Research
Massey researchers discover new genetic target that could shape the future of liver cancer treatmentJun 23, 2025
Research
Virginia health leaders emphasize community impact, collaboration at Virginia Public Health Summit on CancerJun 10, 2025

Get access to new, innovative care
Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Find a provider
Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.